Abstract
TRCC represent a rare and aggressive subgroup of RCC. While 1L therapy recommendations and clinical prognostication of pts with clear-cell RCC are well-known, data on TRCC clinical behavior are limited. TRCC is reported to be an immune cold tumor and the data surrounding 1L ICT is scarce.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have